{"product_id":"new-product-581558","title":"ACTA2 Monoclonal Antibody","description":"\u003cp\u003eThe protein encoded by this gene belongs to the actin family of proteins, which are highly conserved proteins that play a role in cell motility, structure and integrity. Alpha, beta and gamma actin isoforms have been identified, with alpha actins being a major constituent of the contractile apparatus, while beta and gamma actins are involved in the regulation of cell motility. This actin is an alpha actin that is found in skeletal muscle. Defects in this gene cause aortic aneurysm familial thoracic type 6. Multiple alternatively spliced variants, encoding the same protein, have been identified.\u003c\/p\u003e\n\u003cp\u003eIntroducing the ACTA2 Monoclonal Antibody, a cutting-edge pharmaceutical innovation designed to revolutionize the field of medical research and treatment. This groundbreaking product is meticulously crafted to target and interact with the ACTA2 protein, offering unprecedented therapeutic potential for a wide range of clinical applications.\u003cbr\u003e\u003cbr\u003eThe ACTA2 Monoclonal Antibody is meticulously engineered using state-of-the-art technology, ensuring exceptional specificity and affinity towards the ACTA2 protein. This antibody exhibits remarkable binding capabilities, enabling precise and efficient recognition of the target protein, thereby facilitating accurate diagnosis and treatment of associated disorders.\u003cbr\u003e\u003cbr\u003eWith its exceptional potency, the ACTA2 Monoclonal Antibody holds immense promise in the realm of cardiovascular diseases. By selectively targeting the ACTA2 protein, this innovative pharmaceutical agent presents a novel approach to combat various ailments, including aortic aneurysms, thoracic aortic dissections, and other vascular disorders. Its ability to modulate the ACTA2 protein's function opens up new avenues for therapeutic interventions, potentially revolutionizing the treatment landscape for these debilitating conditions.\u003cbr\u003e\u003cbr\u003eFurthermore, the ACTA2 Monoclonal Antibody's versatility extends beyond cardiovascular disorders. Its unique mechanism of action renders it a valuable tool in the realm of cancer research and treatment. By precisely targeting the ACTA2 protein, this antibody holds the potential to disrupt tumor growth and metastasis, offering a promising avenue for the development of novel anti-cancer therapies.\u003cbr\u003e\u003cbr\u003eIn addition to its exceptional efficacy, the ACTA2 Monoclonal Antibody boasts an impeccable safety profile. Rigorous testing and quality control measures ensure that this pharmaceutical product meets the highest standards of safety and reliability. Its well-tolerated nature and minimal side effects make it an ideal candidate for clinical applications, instilling confidence in healthcare professionals and patients alike.\u003cbr\u003e\u003cbr\u003eThe ACTA2 Monoclonal Antibody represents a paradigm shift in medical research and treatment. Its unrivaled specificity, potency, and safety profile make it a game-changer in the field of therapeutics. With its potential to revolutionize the management of cardiovascular diseases and contribute to advancements in cancer research, this innovative pharmaceutical agent holds immense promise for improving patient outcomes and transforming the landscape of modern medicine.\u003c\/p\u003e","brand":"BT Lab","offers":[{"title":"100ul \/ Mouse \/ Primary antibody","offer_id":47548550971672,"sku":"BT-MCA0135","price":300.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/BT_Lab_7037c675-0590-41e9-9667-9d9dfbcfdfec.png?v=1705696236","url":"https:\/\/danabiosci.com\/products\/new-product-581558","provider":"Dana Bioscience","version":"1.0","type":"link"}